Related Experiment Video

Updated: Oct 5, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Inhibition of cellular proliferation by drug targeting of cyclin-dependent kinases

I Pérez-Roger1, C Ivorra, A Díez

  • 1Instituto de Biomedicina de Valencia (IBV-CSIC), Spanish Council for Scientific Research.

Current Pharmaceutical Biotechnology
|July 27, 2001
PubMed

Insights

Targeting cell cycle regulators like cyclin-dependent kinases (CDKs) offers a promising antiproliferative therapy for diseases such as cancer. This review explores CDK inhibitors

Area of Science:

  • Cellular Biology
  • Pharmacology
  • Oncology

Background:

  • Abnormal cellular proliferation underlies diseases like cancer, atherosclerosis, and post-angioplasty restenosis.
  • Cell cycle progression is regulated by cyclin-dependent kinases (CDKs) complexed with cyclins.
  • Active CDK/cyclin complexes phosphorylate key proteins such as the retinoblastoma protein (pRb).

Purpose of the Study:

  • To review the therapeutic potential of targeting cyclin-dependent kinases (CDKs).
  • To discuss drugs that inhibit CDK activity for antiproliferative effects.
  • To examine the application of CDK inhibitors in preclinical and clinical settings.

Main Methods:

  • Literature review of studies on CDK inhibitors.
  • Analysis of data from animal models and human clinical trials.
  • Discussion of compounds targeting CDK activity.

Main Results:

  • CDK inhibitors demonstrate antiproliferative effects by suppressing cell growth.
  • Targeting CDKs is a viable therapeutic strategy for various proliferative diseases.
  • Evidence from animal models and clinical trials supports the efficacy of CDK-targeted therapies.

Conclusions:

  • Antiproliferative therapies targeting cell cycle machinery, specifically CDKs, hold significant therapeutic promise.
  • CDK inhibitors represent a key class of drugs for treating proliferative disorders.
  • Further research and clinical application of CDK inhibitors are warranted.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.